(Q38150978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Deborah L. White

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

2

T P Hughes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

9 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

294-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Multiple molecular mechanisms for multidrug resistance transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

ABC efflux pump-based resistance to chemotherapy drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Role reversal for anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Modulation of human BCRP (ABCG2) activity by anti-HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Functional consequence of MDR1 expression on imatinib intracellular concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Interaction of imatinib mesilate with human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Basic local alignment search tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

7 January 2021

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.208

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json

release_idjfs2hv3rgylbwpumy42u4eqe

27 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/idjfs2hv3rgylbwpumy42u4eqe

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24107928%20AND%20SRC:MED&resulttype=core&format=json